Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China

Diagnostic Pathology

Volumn 6, Issue 1, 2011, Pages

  Song, Qingbin ^a   Wang, Deguang ^b   Lou, Yi ^a   Li, Changsi ^a   Fang, Changqing ^a,c   He, Xiangmin ^a   Li, Jianhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 404 Hospital of People's Liberation Army   (China)

^c Department of pathology ^*  (China)

Author keywords

Ck19; Galectin 3; Ki67; Papillary thyroid carcinoma; Tg

Indexed keywords

CYTOKERATIN 19; GALECTIN 3; KI 67 ANTIGEN; THYROGLOBULIN; TUMOR MARKER;

ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CHINA; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; NODULAR GOITER; PATHOLOGY; THYROID GLAND; THYROID TUMOR;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHINA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GALECTIN 3; GOITER, NODULAR; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; KI-67 ANTIGEN; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 83755194960     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-6-126     Document Type: Article

References (33)

1. Nikiforov YE. Thyroid tumors: classification and general considerations. Diagnostic Pathology and Molecular Genetics of the Thyroid 2009, 94-102. Lippincott Williams & Wilkins, Baltimore, MA, Nikiforov YE, Biddinger PW, Thompson LDR.
2. DeVita VT, Hellman JS, Rosenberg SA. Cancer: principles and practice of oncology. Lippincott Williams & Wilkins 2008, 1674-1699.
3. Sethi K, Sarkar S, Das S, Mohanty B, Mandal M. Biomarkers for the diagnosis of thyroid cancer. J Exp Ther Oncol 2010, 8:341-352.
4. Kato MA, Fahey TJ. Molecular markers in thyroid cancer diagnostics. Surg Clin North Am 2009, 89:1139-1155. 10.1016/j.suc.2009.06.012, 19836489.
5. Nikiforov YE. Molecular analysis of thyroid tumors. Mod Pathol Suppl 2011, 2:34-43.
6. Ito Y, Miyauchi A, Kakudo K, Hirokawa M, Kobayashi K, Miya A. Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma. World J Surg 2010, 34:3015-21. 10.1007/s00268-010-0746-3, 20703465.
7. Vierlinger K, Mansfeld MH, Koperek O, Nöhammer C, Kaserer K, Leisch F. Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics 2011, 6;4:30. 3229454, 22118688.
8. Tan A, Etit D, Bayol U, Altinel D, Tan S. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol 2011, 15:108-116. 10.1016/j.anndiagpath.2010.11.005, 21315633.
9. Fryknäs M, Wickenberg-Bolin U, Göransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Höög A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A. Molecular markers for discrimination of benign and malignant follicular thyroid tumors. Tumour Biol 2006, 27:211-220. 10.1159/000093056, 16675914.
10. Magro G, Cataldo I, Amico P, Torrisi A, Vecchio GM, Parenti R, Asioli S, Recupero D, D'Agata V, Mucignat MT, Perris R. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic marker and therapeutic target. Thyroid 2011, 21:267-277. 10.1089/thy.2010.0173, 21323588.
11. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM. Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol 2010, 176:2067-2081. 10.2353/ajpath.2010.090353, 2861072, 20363921.
12. Barut F, Onak Kandemir N, Bektas S, Bahadir B, Keser S, Ozdamar SO. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. Endocr Pathol 2010, 21:80-89. 10.1007/s12022-010-9114-y, 20198455.
13. Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park do J, Jang HC, Park SH, Cho BY, Park SY. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27 (kip1) in the differential diagnosis of thyroid nodules. J Korean Med Sci 2007, 22:621-628. 10.3346/jkms.2007.22.4.621, 2693809, 17728499.
14. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008, 3:5. 10.1186/1746-1596-3-5, 2267445, 18254952.
15. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005, 18:48-57. 10.1038/modpathol.3800235, 15272279.
16. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin-19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005, 47:391-401. 10.1111/j.1365-2559.2005.02221.x, 16178894.
17. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed for malin-fixed paraffin sections. J Pathol 1992, 168:357-363. 10.1002/path.1711680404, 1484317.
18. Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002, 198:157-162. 10.1002/path.1185, 12237874.
19. Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin HD, Luo M, S-Zhan Su HX, Zhou SB, Xie KQ. Comparative analysis of protein expression in differentiated thyroid tumours: a multicentre study. J Int Med Res 2009, 37:927-938.
20. Carpi A, Mechanick JI, Saussez S, Nicolini A. Thyroid tumor marker genomics and proteomics: diagnostic and clinical implications. J Cell Physiol 2010, 224:612-619. 10.1002/jcp.22187, 20578236.
21. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, Schlumberger M. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999, 84:3228-3234. 10.1210/jc.84.9.3228, 10487692.
22. Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 2002, 87:4806-4810. 10.1210/jc.2002-020094, 12364477.
23. Raimond J, Zimonjic DB, Mignon C, Mattei M, Popescu NC, Monsigny M, Legrand A. Mapping of the galectin-3 gene (LGALS3) to human chromosome 14 at region 14q21-22. Mamm Genome 1997, 8:706-707. 10.1007/s003359900548, 9271684.
24. Türköz HK, Oksüz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 2008, 19:92-96. 10.1007/s12022-008-9033-3, 18581271.
25. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998, 58:3015-3020.
26. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000, 31:428-433. 10.1053/hp.2000.6534, 10821488.
27. Kovàcs RB, Földes J, Winkler G, Bodó M, Sápi Z. The investigation of galectin-3 in diseases of thyroid gland. Eur J Endocrinol 2003, 149:449-453. 10.1530/eje.0.1490449, 14585093.
28. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357:1644-1650. 10.1016/S0140-6736(00)04817-0, 11425367.
29. Erkiliç S, Aydin A, Koçer NE. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid. Endocr Pathol 2002, 13:207-211. 10.1385/EP:13:3:207, 12446919.
30. Fonseca E, Nesland JM, Höie J, Sobrinho-Simões M. Pattern of expression of intermediate cytokeratin filaments in the thyroid gland: an immunohistochemical study of simple and stratified epithelial-type cytokeratins. Virchows Arch 1997, 430:239-245. 10.1007/BF01324808, 9099982.
31. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC) - like nuclear alterations expresses molecular markers of PTC. Histopathology 2004, 45:39-46. 10.1111/j.1365-2559.2004.01876.x, 15228442.
32. Rossi ED, Raffaelli M, Mule'' A, Miraglia A, Lombardi CP, Vecchio FM, Fadda G. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. Histopathology 2006, 48:795-800. 10.1111/j.1365-2559.2006.02428.x, 16722927.
33. Schelfhout LJ, Van Muijen GN, Fleuren GJ. Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma. Am J Clin Pathol 1989, 92:654-658.